Abstract
OBJECTIVES: We investigated the relationship between the degree of fibrosis and endometrial cancer (EC) by calculating the fibrosis-4 (FIB-4) score, a noninvasive marker for measuring the severity of liver fibrosis. MATERIALS AND METHODS: Liver function tests, platelet (PLT) values, abdominal ultrasonography (USG), and magnetic resonance imaging (MRI) reports were analyzed retrospectively before, after, and at diagnosis in patients with EC. RESULTS: The study included 38 patients diagnosed with EC. The median FIB-4 score was calculated as 1.15 (minimum: 0.46-maximum: 3.72). When endometroid (type 1 EC) and nonendometroid (type 2 EC) were compared, the FIB-4 score was higher in type one patients (1.16 [0.46-3.72] and 1.01 [0.53-2.96], respectively). However, there was no significant difference between the two groups (P = 0.961). There was no significant difference between the groups in terms of aspartate aminotransferase, alanine aminotransferase, and PLT parameters before diagnosis, at the time of diagnosis, and after treatment. Gamma-glutamyl transferase (GGT) level was significantly higher in the type 1 group in the prediagnosis period (P = 0.016). In the posttreatment period, GGT was higher in the type 2 group (P = 0.020). For PLT level, there was a statistically significant difference between all three periods only in the type 1 group (P < 0.001). CONCLUSION: FIB-4 score was higher in patients with type 1 EC, which is more associated with obesity and hormones. In addition, prediagnostic values of GGT and PLT were statistically significantly higher in the type 1 group. Our study needs further studies to support FIB-4 score and biochemical GGT and PLT as biochemical markers in patients with type 1 EC.